Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration on Monday approved Pfizer Inc's drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.